查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 Scopolamine全球市场
市场调查报告书
商品编码
1153801

2022-2029 Scopolamine全球市场

Global Scopolamine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

Scopolamine俗称东莨菪碱，是一种天然或合成的托烷类生物碱和抗胆碱药。形式上，它用于治疗晕车和术后噁心呕吐。Scopolamine还可以治疗胃和肠道问题，例□□如痉挛性肌肉疾病、憩室炎、肠易激综合征和帕金森病。

市场动态

推动全球Scopolamine市场的主要因素不仅是消化系统，还有影响消化系统的饮食习惯和随意的生活方式。Scopolamine用于治疗急性眩晕，增加了眩晕的患病率并促进了市场增长，心理压力被认为是晕动病的重要因素之一。

由于世界上癌症数量的增加，预计该市场将会增长。

据世界卫生组织统计，2020年死亡人数将达到1000万，每6人中就有1人死于癌症。其中约 70% 发生在低收入和中等收入国家，最常见的是乳腺癌（2020 年 226 万例）、肺癌（2020 年约 221 万例）和结直肠癌（2020 年 193 万例） ). 案例).因此，化学疗法正在兴起，导致对Scopolamine製剂的需求。因此，上述因素预计将在预测期内推动市场增长。

预计Scopolamine药物副作用和产品停产会阻碍市场增长。

然而，Scopolamine的副作用和某些市场参与者的产品停产将阻碍预测期内全球Scopolamine市场的增长。例如，Scopolamine有常见的副作用，如激动、瞳孔散大、放大、视力模糊、意识模糊和眼睛对光的敏感性增加。此外，Perrigo 出于运营原因停止销售Scopolamine透皮系统，在预测期内减缓了全球Scopolamine市场的增长。

COVID-19 影响分析

由于慢性病导致外科手术数量减少，持续的 COVID-19 大流行对全球Scopolamine市场产生了负面影响。例如，根据国家生物技术信息中心 2020 年 5 月的统计数据，外科手术受到所有危机管理特殊规则的严重影响。大流行影响了工作方法、外科手术、微创手术、手术室工作流程、患者和员工安全、培训、教育等。另一方面，鼓励外科团队通过尽可能进行电话和视频咨询并停止不必要的随访来减少患者的参与。因此，手术次数更少，对麻醉、麻醉镇痛药和用于预防术后噁心和呕吐的Scopolamine透皮贴剂的需求也更少。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 全球癌症患病率上升预计将推动市场增长。
    • 约束因素
      • Scopolamine製剂的副作用和产品停产预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章公式

  • 药片
  • 糖浆
  • 透皮贴剂配方
  • 注射
  • 其他

第八章应用

  • 噁心
  • 晕车

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第12章公司简介

  • Baxter International Inc.
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • GlaxoSmithKline plc.
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemical Corporation

第13章 世界Scopolamine-DataM

简介目录
Product Code: DMPH738

Market Overview

The global scopolamine market size was valued around US$ YY million in 2021 and is expected to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Scopolamine, commonly known as hyoscine or devil's breath, is a tropane alkaloid and anticholinergic medication that is naturally or synthetically manufactured. It is formally used to treat motion sickness and postoperative nausea and vomiting. Scopolamine may also treat stomach or intestine issues such as spastic muscular states, diverticulitis, irritable bowel syndrome, and Parkinson-like symptoms.

Market Dynamics

Major factors driving the global scopolamine market are food habits and casual lifestyles, which affect the digestive system as well as the gastrointestinal system; scopolamine is used to treat acute vertigo, increase the prevalence of dizziness, also helps in market growth, and even psychological stress is considered to one of the significant contributor to motion sickness.

The increasing prevalence of cancer worldwide is expected to drive market growth.

According to the WHO statistics, cancer accounted for ten million deaths in the year 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020). Therefore, it has led to an increase in chemotherapy, which led to the demand for scopolamine drugs. Thus, from the above factors, the market is expected to drive market growth in the forecast period.

Side effects and product discontinuation of scopolamine drugs are expected to hamper market growth.

However, the side effects of scopolamine and product discontinuation by certain market players hamper the global scopolamine market growth during the forecast period. For instance, scopolamine has common as Agitation, less common side effects such as dilated, bigger, or enlarged pupils (black part of the eye), blurred vision or other changes in vision, confusion, and increased sensitivity of the eyes to light. Furthermore, Perrigo has discontinued the scopolamine transdermal system due to business reasons, thus, slowing the global scopolamine market growth during the forecast.

COVID-19 Impact Analysis

The ongoing COVID-19 pandemic has negatively impacted the worldwide scopolamine market, owing to a decline in the number of surgical operations resulting from chronic conditions. For instance, according to National Center for Biotechnology Information statistics in May 2020, the surgical practice was greatly impacted by all special rules to manage the crisis. The pandemic impacted working methods, surgical procedures, minimally invasive surgery, theatre workflow, patient and staff safety, training, and education. In contrast, surgical teams were encouraged to offer phone or video consultations wherever possible and cancel non-essential follow-ups to reduce patient interaction. As a result, the number of surgery procedures was reduced, as was the necessity for the scopolamine transdermal patch, which was used to prevent nausea and vomiting following anesthesia, narcotic pain medications, and surgery.

Segment Analysis

Transdermal Patches segment is expected to hold the largest market share in scopolamine

The transdermal patches segment accounted for the largest market share in 2021. The segment benefits because they are preferred for their ease of use, low cost, and availability. The patch is placed behind the ear on the hairless skin and is used to relieve motion sickness caused by anesthetic during surgery. Furthermore, transdermal scopolamine can be eliminated from the body when it is no longer needed. For instance, Novartis AG, Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg is a prescription drug used to treat the symptoms of vomiting caused by motion sickness from anesthesia. Therefore, it has increased the demand for scopolamine transdermal patches. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global scopolamine

North America region is accounted for the largest market share in 2021. The increasing prevalence of cancer-related surgeries, rising awareness of transdermal scopolamine patches among people, product launches and acquisition and collaborations of market players and FDA approvals in the region are the factors drive the market in the period. For instance, according to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Besides, cancer-related surgeries have also increased with the increasing demand for scopolamine drugs to treat nausea and vomiting.

Moreover, Ingenus Pharmaceuticals, LLC (Riconpharma LLC.) received approval from the United States Food and Drug Administration in December 2021 to manufacture the generic variant of Transderm-Scop (skin patch). As a result, such advancements tend to boost the region's studied market. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the scopolamine market are: Baxter International Inc., GlaxoSmithKline plc., Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia and Fine Chemical Corporation.

On March 2, 2022, Athira Pharma, Inc. used scopolamine, a novel small molecule candidate for Parkinson's disease dementia, Alzheimer's, and Dementia with Lewy bodies, and ATH-1020, an orally accessible, brain-penetrant small molecule candidate for neuropsychiatric diseases.

Novartis AG:

Overview:

Novartis AG is a multinational pharmaceutical company based out of Switzerland. The company engages in developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develop, manufactures, distributes and sells patented pharmaceuticals and comprises two business units: Novartis Oncology and Novartis Pharmaceuticals. Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments. The Sandoz segment develops, manufactures and markets finished dosage form medicines and intermediary products, including active pharmaceutical ingredients.

Product Portfolio:

Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg: Transderm Scop is a prescription medicine used to treat the symptoms of nausea or vomiting caused by motion sickness or from anesthesia.

The global scopolamine report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of cancer worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects and product discontinuation of scopolamine drugs are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Dosage Form

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 7.1.2. Market Attractiveness Index, By Dosage Form
  • 7.2. Tablets*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Syrups
  • 7.4. Transdermal Patches
  • 7.5. Injections
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Nausea*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Motion Sickness

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital pharmacies*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Baxter International Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline plc.
  • 12.3. Novartis AG
  • 12.4. Perrigo Company plc.
  • 12.5. Caleb Pharmaceuticals, Inc.
  • 12.6. Myungmoon Pharma Co. LTD.
  • 12.7. Alchem International
  • 12.8. Phytex Australia
  • 12.9. Centroflora-Cms
  • 12.10. Alkaloids of Australia
  • 12.11. Fine Chemical Corporation

LIST NOT EXHAUSTIVE

13. Global Scopolamine - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us